• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿托西班用于保胎治疗:妊娠24周前早产管理的经验

Tocolysis with atosiban: experience in the management of premature labor before 24 weeks of pregnancy.

作者信息

Richter Oliver N, Dorn C, van de Vondel P, Ulrich U, Schmolling J

机构信息

Department of Obstetrics and Gynecology, University of Bonn School of Medicine, Sigmund-Freud-Strasse 25, 53105 Bonn, Germany.

出版信息

Arch Gynecol Obstet. 2005 Jun;272(1):26-30. doi: 10.1007/s00404-004-0652-8. Epub 2004 Jul 23.

DOI:10.1007/s00404-004-0652-8
PMID:15909190
Abstract

OBJECTIVE

Atosiban has been shown to be an effective tocolytic agent with a low rate of side effects during 24 to 33 weeks of gestation. Atosiban acts through selective, competitive inhibition of both oxytocin and vasopressin, so that there are reasons to assume that a tocolytic effect can also be achieved earlier in the pregnancy.

STUDY DESIGN

In this prospective, randomized pilot study, 20 women in the 18th through 24th week of gestation who presented at our hospital with preterm labor were treated with atosiban. In the control group 20 women received saline infusions. All patients received antibiotic therapy. A cervical cerclage was performed when indicated as was correction of the vaginal pH.

RESULTS

The tocolytic effect began after 3-10 min (median: 6.5 min). Treatment time until the complete absence of contractions was 3-12 h (median: 7.5 h). Pregnancies were prolonged between 11.1 and 21.7 weeks (median: 15.6 weeks) in the atosiban group vs. 10.5-19.1 weeks in the control group. If well tolerated, atosiban was continued. There were no significant alterations in the routine laboratory parameters, circulation parameters, and fluid balance.

CONCLUSION

In summary, atosiban showed itself to be effective for tocolytic treatment for premature labor, even during 18 and 24 weeks of pregnancy, while exhibiting its known, favorable profile of side effects.

摘要

目的

阿托西班已被证明是一种有效的宫缩抑制剂,在妊娠24至33周期间副作用发生率较低。阿托西班通过对催产素和血管加压素的选择性竞争性抑制发挥作用,因此有理由推测在妊娠早期也能实现宫缩抑制效果。

研究设计

在这项前瞻性随机试验研究中,20名妊娠18至24周因早产前来我院就诊的女性接受了阿托西班治疗。对照组20名女性接受生理盐水输注。所有患者均接受抗生素治疗。如有指征则进行宫颈环扎术,并纠正阴道pH值。

结果

宫缩抑制效果在3 - 10分钟后开始(中位数:6.5分钟)。直至宫缩完全消失的治疗时间为3 - 12小时(中位数:7.5小时)。阿托西班组妊娠延长了11.1至21.7周(中位数:15.6周),而对照组为10.5至19.1周。如果耐受性良好,则继续使用阿托西班。常规实验室参数、循环参数和液体平衡均无显著变化。

结论

总之,阿托西班对早产的宫缩抑制治疗显示出有效性,即使在妊娠18至24周期间,同时展现出其已知的良好副作用特征。

相似文献

1
Tocolysis with atosiban: experience in the management of premature labor before 24 weeks of pregnancy.阿托西班用于保胎治疗:妊娠24周前早产管理的经验
Arch Gynecol Obstet. 2005 Jun;272(1):26-30. doi: 10.1007/s00404-004-0652-8. Epub 2004 Jul 23.
2
Atosiban and nifedipine in acute tocolysis: a comparative study.阿托西班与硝苯地平用于急性宫缩抑制:一项对比研究。
Eur J Obstet Gynecol Reprod Biol. 2006 Sep-Oct;128(1-2):129-34. doi: 10.1016/j.ejogrb.2005.12.010. Epub 2006 Jan 30.
3
Effectiveness and safety of the oxytocin antagonist atosiban versus beta-adrenergic agonists in the treatment of preterm labour. The Worldwide Atosiban versus Beta-agonists Study Group.催产素拮抗剂阿托西班与β-肾上腺素能激动剂治疗早产的有效性和安全性。全球阿托西班与β-激动剂研究组。
BJOG. 2001 Feb;108(2):133-42.
4
Treatment of preterm labor with the oxytocin antagonist atosiban.使用缩宫素拮抗剂阿托西班治疗早产。
Am J Perinatol. 1996 Apr;13(3):143-6. doi: 10.1055/s-2007-994312.
5
Clinical practice evaluation of combination of atosiban, ritodrine and ketoprofen for inhibiting preterm labor.阿托西班、利托君和酮洛芬联合用于抑制早产的临床实践评估
Minerva Ginecol. 2007 Oct;59(5):481-9.
6
Multicentre, parallel group, randomised, single-blind study of the safety and efficacy of atosiban versus ritodrine in the treatment of acute preterm labour in Korean women.阿托西班与利托君治疗韩国女性急性早产安全性和有效性的多中心、平行组、随机、单盲研究
BJOG. 2006 Nov;113(11):1228-34. doi: 10.1111/j.1471-0528.2006.01053.x. Epub 2006 Sep 15.
7
Barusiban suppresses oxytocin-induced preterm labour in non-human primates.巴鲁司班可抑制非人类灵长类动物中催产素诱导的早产。
BMC Pregnancy Childbirth. 2007 Jun 1;7 Suppl 1(Suppl 1):S15. doi: 10.1186/1471-2393-7-S1-S15.
8
Atosiban versus usual care for the management of preterm labor.阿托西班与常规护理用于早产管理的比较
J Perinat Med. 2007;35(4):305-13. doi: 10.1515/JPM.2007.078.
9
[Clinical experience of using oxytocin antagonist atosiban in the rescue therapy of preterm labour].使用缩宫素拮抗剂阿托西班抢救早产的临床经验
Zhonghua Fu Chan Ke Za Zhi. 2008 Feb;43(2):81-4.
10
The oxytocin antagonist atosiban versus the beta-agonist terbutaline in the treatment of preterm labor. A randomized, double-blind, controlled study.催产素拮抗剂阿托西班与β-激动剂特布他林治疗早产的对比:一项随机、双盲、对照研究。
Acta Obstet Gynecol Scand. 2001 May;80(5):413-22.

引用本文的文献

1
Tocolytic Therapy Inhibiting Preterm Birth in High-Risk Populations: A Systematic Review and Meta-Analysis.抑制高危人群早产的宫缩抑制剂治疗:一项系统评价和荟萃分析
Children (Basel). 2023 Feb 24;10(3):443. doi: 10.3390/children10030443.
2
Tocolytics for delaying preterm birth: a network meta-analysis (0924).用于延迟早产的保胎药物:一项网状荟萃分析 (0924)。
Cochrane Database Syst Rev. 2022 Aug 10;8(8):CD014978. doi: 10.1002/14651858.CD014978.pub2.
3
Tocolysis for inhibiting preterm birth in extremely preterm birth, multiple gestations and in growth-restricted fetuses: a systematic review and meta-analysis.
用于抑制极早早产、多胎妊娠和生长受限胎儿早产的宫缩抑制剂:一项系统评价和荟萃分析。
Reprod Health. 2016 Jan 14;13:4. doi: 10.1186/s12978-015-0115-7.
4
Tocolytics used as adjunctive therapy at the time of cerclage placement: a systematic review.宫颈环扎术时辅助使用保胎药物治疗:系统评价。
J Perinatol. 2015 Aug;35(8):561-5. doi: 10.1038/jp.2015.38. Epub 2015 Apr 23.
5
Oxytocin receptor antagonists for inhibiting preterm labour.用于抑制早产的催产素受体拮抗剂。
Cochrane Database Syst Rev. 2014 Jun 6;2014(6):CD004452. doi: 10.1002/14651858.CD004452.pub3.
6
Placental leucine aminopeptidase- and aminopeptidase A- deficient mice offer insight concerning the mechanisms underlying preterm labor and preeclampsia.胎盘亮氨酸氨肽酶和氨肽酶A缺陷小鼠为早产和先兆子痫的潜在机制提供了见解。
J Biomed Biotechnol. 2011;2011:286947. doi: 10.1155/2011/286947. Epub 2010 Dec 6.